Lyell Immunopharma (LYEL) Registration filing summary

Company overview and business model

• Late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies for cancer patients, targeting both hematologic malignancies and solid tumors.

• Focuses on engineering patients' immune cells with proprietary enhancements to improve cancer cell killing and durability of response.

• Incorporated in June 2018 in Delaware, headquartered in South San Francisco, CA.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling stockholders; only registration expenses are covered by the company.

• Selling stockholders bear all selling commissions, transfer taxes, and related costs.

Risk factors and disclosures

• Investment involves a high degree of risk, with potential for loss of all or part of investment.

• Risks are detailed in the most recent Annual Report on Form 10-K and subsequent Quarterly Reports, incorporated by reference.

• Forward-looking statements are subject to significant uncertainties and actual results may differ materially.